Brookfield to acquire a $4.8B stake in Oaktree Capital Management
By Nikita Chaurasia  Date: 2019-03-15

Brookfield to acquire a $4.8B stake in Oaktree Capital Management
  • With the acquisition, Brookfield aims to compete with industry giants such as the Blackstone Group.
     
  • The deal makes Oaktree the second American alternative-asset manager to carry out such a transaction in recent years.

Brookfield Asset Management Inc., (Brookfield), a Canadian alternative-asset management firm, has reportedly announced the $4.8 billion majority stake acquisition of California-based asset management firm, Oaktree Capital Management (Oaktree).

Reports cite, the deal makes Oaktree the second American alternative-asset manager to carry out such a transaction in recent years. With the acquisition, Brookfield aims to compete with industry giants such as the Blackstone Group.

According to a report by Bloomberg, under the terms of the agreement, Brookfield would be acquiring a 62% majority stake in Oaktree Capital in a cash & stock deal. The two firms would together have over $475 billion worth of combined assets under their management and a fee-related annual revenue of $2.5 billion.

The Chief Executive Officer of Brookfield Asset Management, Bruce Flatt stated that the deal enables the company to significantly broaden its product portfolio to include one of the world’s finest credit platforms, which boasts of a value-propelled contrarian investment style that is consistent with the company’s.

For the record, leading industry player Blackstone boasted of $472 billion worth of assets under its management by the end of 2018. This valuation does not account for the debt, if the debt is counted, assets under Blackstone’s management would be around $650 billion.

As part of the acquisition deal, Oaktree shareholders would be able to exchange their respective shares for either 1.0770 Brookfield Class A shares or for a cash payment of $49 per share. The proposed offer is approximately 12.4% premium of Oaktree Class A shares, as per the latest closing price.

According to reports, the amount to be paid for the Oaktree majority stake would be made 50% in cash and 50% stock.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...